Evolution of decitabine development: Accomplishments, ongoing investigations, and future strategies
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Decitabine (5‐aza‐2′‐deoxycytidine) is a hypomethylating agent with a dual mechanism of action: reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses. The original studies in the 1980s used decitabine as a classical anticancer drug, at its maximum clinically tolerated dose, 1500 to 2500 mg/m 2 per course. At these doses, decitabine was found to be active in leukemia, but was associated with delayed and prolonged myelosuppression. After a better understanding of epigenetics in cancer and the role of decitabine in epigenetic (hypomethylating) therapy was gained, it was reevaluated at approximately 1/20th of the previous doses (ie, at ‘optimal biologic’ doses that modulate hypomethylation). In these dose schedules of decitabine (100 to 150 mg/m 2 per course), the drug was found to be active with manageable side effects in patients with myelodysplastic syndromes (MDS) and other myeloid tumors. Optimizing dosing schedules of decitabine to maximize hypomethylation (low dose, high dose intensity, and multiple cycles) have further improved results, suggesting that decitabine is an active therapy that alters the natural course of MDS. Combination therapies that augment the epigenetic effect of decitabine will likely improve responses and extend its use for the treatment of other malignancies. Cancer 2008. ©2008 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA methylation patterns and epigenetic memory
Bird, A. (2002) · Genes & Development · doi:10.1101/gad.947102 · Cited by 7,124
Gene Silencing in Cancer in Association with Promoter Hypermethylation
Herman, J. G., & Baylin, S. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023075 · Cited by 3,422 · cited 1×
“silencing is exploited by cancers to fully express the malignant phenotype.(3) Evidence supporting a role of epigenetic gene silencing in tumorigenesis stems from studies revealing a large number of genes that are silenced by aberrant DNA methylation in different types of cancers, many of which are involved in the con…”
BackgroundThe Role of DNA Methylation in Mammalian Epigenetics
Jones, P. A., & Takai, D. (2001) · Science · doi:10.1126/science.1063852 · Cited by 2,070 · cited 1×
“Chromatin remodeling is a powerful mechanism of regulating gene expression and protein function.(2) In extreme states, chromatin remodeling can permanently repress expression of a gene, a situation termed ‘epigenetic silencing.”
BackgroundAlterations in DNA Methylation: A Fundamental Aspect of Neoplasia
(1997) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60702-2 · Cited by 1,928 · cited 2×
“Preclinical Studies With Decitabine DNA hypermethylation and gene silencing Aberrant DNA methylation is present in many malignancies, with concomitant global hypomethylation and localized hypermethylation.(4) Increased methylation affects regulatory regions located in CpG islands and suppresses gene expression.”
BackgroundCameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G., & Baylin, S. B. (1999) · Nature Genetics · doi:10.1038/5047 · Cited by 1,857 · cited 2×
“This dual effect (hypomethylation/ histone changes) may explain the superior effect of decitabine on gene expression compared with histone deacetylase inhibitors.(28) Decitabine also has significant effects on the expression of genes not silenced by CpG island methylation.”
BackgroundCellular differentiation, cytidine analogs and DNA methylation
Jones, P. A., & Taylor, S. M. (1980) · Cell · doi:10.1016/0092-8674(80)90237-8 · Cited by 1,831 · cited 11×
“At high doses decitabine produces DNA adducts that results in DNA synthesis arrest and cytotoxicity.(10,11) At low doses it induces gene expression profile changes that favor differentiation, reduced proliferation, and/or increased apoptosis.”
BackgroundInfluentialSilverman, L. R., Demakos, E. P., Peterson, B. L., Kornblith, A. B., Holland, J. C., Odchimar-Reissig, R., Stone, R. M., Nelson, D., Powell, B. L., DeCastro, C. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.117 · Cited by 1,825
Cheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580 · cited 1×
“response (CR, PR, or hematologic improvement [HI]) by the new modified International Working Group (IWG) criteria.(51) The 5-day intravenous schedule, which had the highest dose intensity, was selected as optimal.”
MethodKantarjian, H., Issa, J. J., Rosenfeld, C. S., Bennett, J. M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., et al. (2006) · Cancer · doi:10.1002/cncr.21792 · Cited by 1,530 · cited 10×
“In a review of patients on the MDS phase 3 randomized trial, 12 patients treated on the decitabine arm (n 5 9 patients) and on the supportive care arm (n 5 3 patients) were found retrospectively to have AML at baseline by central review.(21) Of the 9 patients treated with decitabine, 5 (56%) achieved an objective resp…”
BackgroundMethodInfluentialSelf-citationIssa, J.-P. J., Garcia-Manero, G., Giles, F. J., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C. S., Cortes, J., et al. (2004) · Blood · doi:10.1182/blood-2003-03-0687 · Cited by 809 · cited 3×
“and its absolute requirement for DNA synthesis for activity, led to a novel phase 1 trial of decitabine in patients with recurrent or refractory leukemia.(31) This study tested low-dose longer exposure schedules, 2344 CANCER June 1, 2008 / Volume 112 / Number 11”
BackgroundSelf-citation
Cited by
Epigenetics in cancer: Targeting chromatin modifications
Ellis, L., Atadja, P. W., & Johnstone, R. W. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0860 · Cited by 479
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Ding, Q., Hu, W., Wang, R., Yang, Q., Zhu, M., Li, M., Cai, J., Rose, P., Mao, J., & Zhu, Y. Z. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01331-9 · Cited by 478
Epigenetic Resensitization to Platinum in Ovarian Cancer
Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W. A., Huang, T., & Nephew, K. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3909 · Cited by 390
Fluorine-containing pharmaceuticals approved by the FDA in 2020: Synthesis and biological activity
Yu, Y., Liu, A., Dhawan, G., Mei, H., Zhang, W., Izawa, K., Soloshonok, V. A., & Han, J. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.05.042 · Cited by 182
Activity-based CRISPR scanning uncovers allostery in DNA methylation maintenance machinery
(2023) · doi:10.7554/elife.80640 · Cited by 16
Metadata
- Authors
- Jabbour, E., Issa, J., Garcia‐Manero, G., & Kantarjian, H.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2008-04-08
- Volume
- 112
- Issue
- 11
- Pages
- 2341-2351
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2043244590
- Cited by
- 224
- References
- 61
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.